NMC
ABOS icon

Nine Masts Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Nine Masts Capital’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,637
Closed -$22.4K – 250
2025
Q4 		$22.4K Buy
+10,637
New +$21.1K ﹤0.01% 99

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Nine Masts Capital's ABOS Position: Q1 2026 in Review

Nine Masts Capital sold out of Acumen Pharmaceuticals (ABOS) in Q1 2026, closing a stake of 10,637 shares — an estimated $22.4K sold.

Nine Masts Capital first reported a position in ABOS in Q4 2025 and held it in 1 quarter. The position peaked at $22.4K in Q4 2025. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Nine Masts Capital reported no remaining Acumen Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Nine Masts Capital sold 10,637 Acumen Pharmaceuticals shares in Q1 2026, an estimated $22.4K.
  • Nine Masts Capital first reported a position in Acumen Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Nine Masts Capital's Acumen Pharmaceuticals position peaked at $22.4K in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Nine Masts Capital's 13F filing for Q1 2026, filed 13 May 2026.